Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 2/20 | 0.64 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.64 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.64 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.64 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.64 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.63 |
| ▸ | CYP1A1 | P04798 | 8/20 | 0.63 |
| ▸ | CYP1B1 | Q16678 | 8/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8237102 | 1.00 | GRIN2D (0.64) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30481109 | 1.00 | GRIN2D (0.64) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2009040 | 1.00 | GRIN2D (0.64) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3739643 | 0.85 | CYP1A1 (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3739640 | 0.85 | CYP1A1 (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3638744 | 0.85 | HPGD (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3638747 | 0.85 | HPGD (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL11747282 | 0.85 | GRIN2D (0.73) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3717558 | 0.84 | LMNA (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3717557 | 0.84 | LMNA (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998005630-A1 | PROCESS FOR THE PREPARATION OF ORGANIC NITRILES | ALLIEDSIGNAL INC. (US) | 1998-02-12 | — | — | WO | claimed |
| CN-113861069-B | Preparation method of nitrile compound | 陕西国际商贸学院 | 2023-06-16 | — | — | CN | disclosed |
| CN-113861069-A | Preparation method of nitrile compound | 陕西国际商贸学院 | 2021-12-31 | — | — | CN | disclosed |
| CN-111244547-B | Electrolyte containing aromatic oxime additive and preparation method and application thereof | 四川虹微技术有限公司 | 2021-09-17 | — | — | CN | disclosed |
| CN-111244547-A | Electrolyte containing aromatic oxime additive and preparation method and application thereof | 四川虹微技术有限公司 | 2020-06-05 | — | — | CN | disclosed |
| EP-2366704-B1 | Inhibitors of serine proteases | VERTEX PHARMA (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2631238-A1 | Spirocyclic inhibitors of serine proteases for the treatment of hcv infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8440706-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-14 | — | — | US | disclosed |
| US-8372873-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| EP-1917269-B1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMA (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1506162-A2 | SYNTHESIS OF BENZONITRILES AND BENZIMIDATES | Genzyme Corporation (US) | 2005-02-16 | — | — | EP | disclosed |
| CN-1151150-C | Non-peptide angiotonin II receptor antagon Jw sartan compounds and its synthesizing process and application | 王建武 | 2004-05-26 | — | — | CN | disclosed |
| US-20030220504-A1 | Synthesis of benzonitriles from substituted benzaldehyde | GENZYME CORPORATION | 2003-11-27 | — | — | US | disclosed |
| WO-2003097582-A2 | SYNTHESIS OF BENZONITRILES AND BENZIMIDATES | GENZYME CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| CN-1369492-A | Non-peptide angiotonin II receptor antagon Jw sartan compounds and its synthesizing process and application | WANG JIANWU (CN) | 2002-09-18 | — | — | CN | disclosed |
| WO-1998005630-A1 | PROCESS FOR THE PREPARATION OF ORGANIC NITRILES | ALLIEDSIGNAL INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| EP-0112524-B1 | TRICHLOROACRYLOYL OXIME DERIVATIVES | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-05-28 | — | — | EP | disclosed |
| US-4581365-A | Trichloroacryloyl oxime fungicides | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-04-08 | — | — | US | disclosed |
| EP-0112524-A1 | Trichloroacryloyl oxime derivatives | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1984-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220504-A1 | Synthesis of benzonitriles from substituted benzaldehyde | FTH1, FGB, DBF4 | GRIN2D 2800/4885GRIN3B 3383/4885GRIN1 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.